The company first plans to launch the generic, which is approved for Type 2 diabetes (Ozempic) and weight loss (Wegovy), in Canada when the patent for semaglutide expires in 2026.
Sandoz spun off from Novartis in October 2023 and focuses on manufacturing generic pharmaceuticals. The company is working on the generic Ozempic drug with the pharmaceutical company Pharmathen.
Read the latest GLP-1 drug updates from Becker’s here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.